Type 2 diabetes mellitus with hypertension
Conditions
Interventions
Patients who were being treated with telmisartan 80mg/day at 8 weeks switched to olmesartan. After 12 weeks of olmesartan treatment, we evaluated blood pressure and laboratory data.
Patients who were
Sponsors
University of Occupational and Environmental Health, Japan
Ashiya central hospital, Nogata central hospital, Hagiwara central hospital, Kitakyushu city Yahata hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All patients with type 2 diabetes mellitus with hypertension vistited our Hospital and approved with this study. They who were being treated with telmisartan 80mg or olumesartan40mg at least for 8 weeks did not reached aim of decrease of blood pressure. Medication other than antihypertensive drug was not changed for 8weeks.
Exclusion criteria
Exclusion criteria: 1)patients treated with insulin therapy. 2)patients who wrere poorly controlled . 3)patients with secondary hypertension. 4)patients on HD. 5)pregnant patients. 6)patients who wrere allergic to telmisartan and olmesartan. 7)patients with heavy liver dysfunction. 8)patients with heavy renal dysfunction(Cre>3mg/dL).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1)decrease of blood pressure 2)achievemenent rate of aim of decreasing blood pressure(<130/80mmHg) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)blood pressure of home 2)metabolic parameters(FPG,HbA1c, FIRI,HOMA-IR,HM-adiponectin) 3)urine albumin 4)inflammatory marker(hs-CRP,IL-6) 5)lipid profiles(TC,TG,HDL-C,LDL-C) | — |
Countries
Japan
Contacts
Public ContactTadashi Arao
Kyushu Rosai Hospital, Moji Medical Center Department of Internal Medicine, Division of Diabetes, Hematology and Collagen Disease
Outcome results
None listed